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Abstract
Background: Carriers of the APOE ε4 allele are at increased risk of developing Alzheimer’s disease (AD), and
have been shown to have reduced cerebral metabolic rate of glucose (CMRgl) in the same brain areas frequently
affected in AD. These individuals also exhibit reduced plasma levels of apolipoprotein E (apoE) attributed to a
specific decrease in the apoE4 isoform as determined by quantification of individual apoE isoforms in APOE ε4
heterozygotes. Whether low plasma apoE levels are associated with structural and functional brain measurements
and cognitive performance remains to be investigated.
Methods: Using quantitative mass spectrometry we quantified the plasma levels of total apoE and the individual
apoE3 and apoE4 isoforms in 128 cognitively normal APOE ε3/ε4 individuals included in the Arizona APOE cohort.
All included individuals had undergone extensive neuropsychological testing and 25 had in addition undergone
FDG-PET and MRI to determine CMRgl and regional gray matter volume (GMV).
Results: Our results demonstrated higher apoE4 levels in females versus males and an age-dependent increase in
the apoE3 isoform levels in females only. Importantly, a higher relative ratio of apoE4 over apoE3 was associated
with GMV loss in the right posterior cingulate and with reduced CMRgl bilaterally in the anterior cingulate and in
the right hippocampal area. Additional exploratory analysis revealed several negative associations between total
plasma apoE, individual apoE isoform levels, GMV and CMRgl predominantly in the frontal, occipital and temporal
areas. Finally, our results indicated only weak associations between apoE plasma levels and cognitive performance
which further appear to be affected by sex.
Conclusions: Our study proposes a sex-dependent and age-dependent variation in plasma apoE isoform levels
and concludes that peripheral apoE levels are associated with GMV, CMRgl and possibly cognitive performance in
cognitively healthy individuals with a genetic predisposition to AD.
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Background
More than two decades after the first report describ-
ing a significantly increased risk of developing late-
onset Alzheimer’s disease (AD) in carriers of the
APOE ε4 allele [1], this allele remains the strongest
genetic risk factor for AD. Recent work further shows
that the presence of the APOE ε4 allele also increases
the risk of dementia with Lewy bodies (DLB) [2]
whereas carriers of the APOE ε2 allele are protected
against developing either of these two disorders [2, 3].
Although there is strong evidence that the presence
of the APOE ε4 allele drives early and more abundant
amyloid-beta (Aβ) pathology in AD, the exact bio-
logical mechanisms underlying the variation in risk of
disease between the different APOE genotypes are not
fully understood. Interestingly, cognitively healthy car-
riers of the APOE ε4 allele exhibit cerebral Aβ accu-
mulation as early as in their third or fourth decade of
life [4, 5]. Amyloid-β plaque pathology appears to be
more prominent in female APOE ε4 carriers [4], who
also are at a greater risk of AD than their male coun-
terparts [6, 7]. Results from augmenting studies sug-
gest an increase specifically in the pool of oligomeric Aβ
in FAD-Tg mice expressing APOE ε4, in synaptosome-
enriched preparations from APOE ε4 carriers and in
APOE ε4 versus APOE ε3 carrier AD patients, of which
the former AD patients exhibit higher levels of oligomeric
Aβ surrounding amyloid plaques [8]. Consistent accumu-
lating evidence further shows that APOE ε4 carriers
devoid of cognitive symptoms exhibit low cerebral meta-
bolic rate of glucose (CMRgl) in the posterior cingulate,
precuneus, parietotemporal and frontal regions [9–13],
and reduced regional gray matter volume (GMV) in the
hippocampus [14] and amygdala [15], all brain regions
known to be affected in AD. Interestingly, some of these
changes can be found in young adults many years prior to
the onset of cognitive dysfunction [16]. Even more com-
pelling, these brain abnormalities appear to be present
very early in life because recent results from a cross-
sectional imaging study on infant APOE ε4 carriers (6–25
months of age) suggest that the white matter myelin water
fraction and GMV are reduced in the precuneus, poster-
ior/middle cingulate, lateral temporal and medial occipito-
temporal regions compared with infant noncarriers [17].
These alterations may render APOE ε4 carriers more sus-
ceptible to AD-related pathology and predict conversion
to AD in individuals with mild cognitive impairment
(MCI) [18, 19]. Studies of APOE ε4-targeted replacement
mice proposed a clear link between early-life stress and
cognitive impairment in middle-aged mice, but whether
these observations are of relevance to humans needs to be
confirmed [20].
At the molecular level, various Aβ-dependent and in-
dependent mechanisms have been suggested to explain
the increased risk of AD in APOE ε4 carriers [21]. For
example, results from numerous studies on animal
models show that the presence of the APOE ε4 allele
promotes Aβ pathology [22]. In support, we and others
have shown that the APOE gene product apolipoprotein
E (apoE) negatively affects cellular Aβ uptake, for in-
stance by glial cells [23–25]. In our work published re-
cently we propose that cellular Aβ uptake is reduced in
the presence of apoE due to competition between apoE
and Aβ for binding to cell surface heparan sulfate pro-
teoglycans (HSPGs) [26]. It has further been shown that
animals expressing different human apoE isoforms ex-
hibit APOE genotype-dependent variations in apoE
levels, with the lowest apoE levels found in apoE4-
expressing animals [27]. Other studies addressing apoE
fluid concentrations in humans with different APOE
genotypes, however, have reported conflicting results
[28–31]. Technical issues were proposed to underlie the
variation in reported apoE levels [28]. This is a valid
concern because the three apoE isoforms only differ in
one or two amino acid residues at positions 112 and 158,
complicating the development of isoform-specific anti-
bodies to be used in immuno-based quantification assays.
To address this concern, we recently developed a specific
multiplexed mass spectrometry-based assay for the abso-
lute quantification of total apoE and individual apoE
isoforms [32]. Employing this method we found that cere-
brospinal fluid (CSF) and plasma levels of total apoE do
not differ between AD patients and nondemented individ-
uals [33]. However, plasma apoE levels were significantly
reduced in APOE ε4 carriers with the lowest levels found
in homozygous individuals, both controls and AD patients.
As concluded from the results derived from APOE ε4 het-
erozygous individuals, the observed lower levels of plasma
apoE in these individuals resulted from a specific reduction
in the levels of the apoE4 isoform. In our previous study,
total plasma apoE in heterozygous APOE ε4 was composed
of roughly 30% apoE4 versus 70% non-apoE4 [33]. Because
we found no difference in CSF or plasma apoE levels be-
tween AD patients and nondemented individuals we spec-
ulated that the peripheral apoE deficiency observed in
APOE ε4 carriers may predispose these individuals to, ra-
ther than cause, neurodegenerative disease. An association
between low levels of plasma apoE and risk of AD was sug-
gested previously by findings from a prospective study of
the Danish general population [34]. In the current study
we aimed to quantify total plasma apoE as well as the
individual apoE isoform levels and their effect on cogni-
tion, CMRgl and GMV in cognitively healthy APOE ε3/ε4
carriers. To our knowledge, this is the first report investi-
gating whether the levels of individual apoE isoforms in
plasma from APOE ε3/ε4 carriers are associated with
GMV and CMRgl, as determined using structural and
functional brain imaging, and cognitive performance.
Nielsen et al. Alzheimer's Research & Therapy  (2017) 9:5 Page 2 of 10
Methods
Study cohort
The included individuals are a sample from the Arizona
APOE Cohort for which recruitment and enrollment
strategies have been described previously [35–37].
Briefly, the Arizona APOE Cohort consists of cognitively
normal individuals residing in Maricopa County, AZ,
USA. Since 1994, residents aged 21 years and older have
been recruited through local media advertisements for
inclusion in a study of cognitive aging. The Arizona
APOE Cohort study subjects underwent APOE genotyp-
ing and agreed to have the test results withheld from
them as part of the study protocol. To be considered for
inclusion, participants had to score at least 27 points on
the Mini-Mental State Examination and exhibit no evi-
dence of depression (10 points or less on the Hamilton
Depression Rating Scale). None of the included individ-
uals met the published criteria for MCI [38] or AD [39]
at study entry. Study subjects were followed and seen in
the clinic every 1–2 years. Blood for plasma analysis was
collected in tubes containing EDTA. Samples were centri-
fuged at 2000 × g at 4 °C for 10 minutes. Centrifuged sam-
ples were aliquoted and immediately frozen at –80 °C in
polypropylene vials pending biochemical analysis. In the
current study, 128 individuals with an APOE ε3/ε4 geno-
type from whom blood samples were drawn at the
same visit or within 1 year of their neuropsycho-
logical assessment (see later) were included. Within
this group, 25 individuals had undergone imaging
(FDG-PET and MRI) plasma sampling and cognitive
testing within the same year. All individuals gave in-
formed written consent to participate in the study
and the study protocol was approved by the institu-
tional review boards of Banner Good Samaritan
Medical Center (now Banner-University Medical Cen-
ter, Phoenix, AZ, USA) and the Mayo Clinic.
ApoE quantification
Plasma total apoE, apoE3 and apoE4 isoform concentra-
tions were quantified using a previously described mass
spectrometry-based multiplex selected reaction monitor-
ing (SRM) assay [32] and the services provided by the
Mayo Clinic Proteomics Core. Briefly, two tryptic peptides
derived from the two major APOE single nucleotide poly-
morphisms (SNP112 and SNP158) were employed for the
quantification of apoE3 and apoE4 isoforms (LAVYQA-
GAR and LGADMEDVR). As a control, total apoE
concentrations were quantified in parallel using a tryptic
peptide with a sequence present in all three known apoE
isoforms (LGPLVEQGR). Plasma samples were diluted
1:100, digested as described previously [32] and analyzed
using liquid chromatography–tandem mass spectrometry
(LC-MS/MS) with a Waters NanoAcquity coupled to a
Thermo Vantage mass spectrometer.
Brain imaging
T1-weighted, three-dimensional, pulse sequence MRI
and FDG-PET data were obtained for each subject
(n = 25) as described previously [40]. All MRI scans
were performed on the same 1.5-T Signa system
(General Electric, Milwaukee, WI, USA) for the T1-
weighted, three-dimensional pulse sequence (radiofre-
quency-spoiled gradient recall acquisition in the
steady state (SPGR), repetition time = 33 ms, echo
time = 5 ms, α = 30°, number of excitations = 1, field
of view = 24 cm, imaging matrix = 256 × 192, slice
thickness = 1.5 mm, scan time = 13:36 min). The re-
constructed images included 128 contiguous horizon-
tal MRI slices with slice thicknesses of 1.5 mm and
in-plane voxel dimensions of 0.94 mm × 1.25 mm.
For FDG-PET, our study personnel consistently
instructed participants to lie quietly with their eyes
closed in the darkened scanner room. All PET scans
were performed on the same HR+ scanner (Siemens,
Knoxville, TN, USA) in the three-dimensional mode.
The procedure included a transmission scan, an intra-
venous injection of 5–8 mCi of FDG and a 60-minute
dynamic sequence of emission scans. The reconstructed
images consist of 63 horizontal slices with a center-to-
center slice separation of 2.46 mm, an axial field of view of
15.5 cm, an in-plane resolution of 4.2–5.1 mm full width at
half-maximum and an axial resolution of 4.6–6.0 mm full
width at half-maximum. PET images (counts relative to
the whole-brain uptake) acquired during the last 30 -
minutes were used for the voxel-based analyses.
The automated brain mapping algorithmic program
voxel-based morphometry (VBM), implemented in Stat-
istical Parametric Mapping (SPM8; Wellcome Trust
Centre for Neuroimaging, London, UK), was used to
process the volumetric T1-MRI data, characterizing the
gray matter spatial distributions and spatially deforming
the individual gray matter maps to the predefined coord-
inate space, as defined by the Montreal Neurological
Institute (MNI) brain template [41]. SPM8 was also used
to spatially deform the individual FDG-PET data to the
same MNI brain template.
General linear model-based, voxel-wise analysis ex-
amined the association of the apoE4/apoE3 ratio with
volumetric MRI-based regional GMV or with FDG-
PET-measured CMRgl respectively. For exploratory
analysis, uncorrected p = 0.005 was chosen for all
imaging-related analyses. This value has been shown
to provide the optimal balance between type-I and
type-II errors [42]. To adjust significance levels for
the number of resolution elements in a-priori regions
known to be affected by AD, previously characterized
independently for volumetric MRI and FDG-PET from
the Alzheimer’s disease Neuroimaging Initiative
(ADNI) project, the association in each of the regions
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of interest was corrected for multiple comparisons
with family-wise error (FWE) correction. A threshold
of p < 0.05 was used via the small volume correction
(SVC) procedure in SPM
Plasma lipid profiling
The majority of the imaged subjects (n = 24) had under-
gone plasma lipid profiling including plasma total chol-
esterol, triglycerides and HDL and LDL cholesterol as
part of the clinical work-up. Plasma lipids were assessed
as described previously [43].
Neuropsychological testing
The neuropsychological test battery administered to the
study participants is described in detail elsewhere [37].
In addition to tests assessing global cognition (the Mini-
Mental State Examination, the Instrumental Activities of
Daily Living and the Structured Psychiatric Interview
from the revised DSM III third edition), more special-
ized tests assessing four cognitive domains including
memory, language, visuospatial and executive functions
were administered. Tests and summary of results for the
study subjects included in the present study are available
in Additional file 1: Table S1.
Statistical analysis
Normal distribution of the data was assessed using the
Shapiro–Wilk W Test. Cognitive test data and total
apoE, apoE3 and apoE4 levels were not normally distrib-
uted, hence nonparametric tests were used throughout
the statistical analyses. Regression analysis was used to
assess statistical associations between imaging data and
apoE levels. If not stated differently, data are presented
as median with range (minimum–maximum) whereas
descriptive data, lipid profiles and cognition test results
are shown as mean ± standard deviation.
Results
Study subject characteristics
A total of 128 individuals, 71% females, were included in
this study. A subset of these individuals (n = 25) had
undergone brain imaging studies. The demographics of
the whole study cohort and imaged group are summa-
rized in Table 1. In the whole cohort, the average age
was slightly higher in the male group (p = 0.03), who also
exhibited a trend toward higher body mass index
compared with the females (p = 0.09). The female group
differed from the male group having 6.7% more non-
Caucasian study participants. The group of females
versus males did not differ with regard to incidence of
diabetes, family history of dementia and average years of
education. No difference was observed between parame-
ters of the whole cohort and the imaged subgroup.
Plasma levels of total apoE and individual apoE3 and
apoE4 isoforms
Total plasma apoE concentrations were similar in the
whole cohort and in the imaged subgroup (Fig. 1a), and
consisted of 78.9% versus 85% apoE3 isoform and 21%
versus 15% apoE4 isoform (Fig. 1a). Total apoE was
strongly and positively correlated to apoE3 levels (Fig. 1b)
in both groups (separate results for imaged group not
shown), whereas apoE4 levels only weakly associated
with total apoE levels (Fig. 1c) (n = 128). Importantly, we
found no significant correlation between the plasma
concentrations of the apoE3 and apoE4 isoforms
(Fig. 1d). We further found no association between
plasma levels of total apoE and individual apoE isoforms,
age at investigation, body max index (BMI), family his-
tory of dementia, incidence of diabetes or total years of
education (data not shown). Because apoE is an import-
ant lipid carrier both in the periphery and in the CNS,
we examined the lipid profiles obtained from a subset of
individuals (n = 24) to assess potential relationships with
apoE. Lipid profiles are presented in Table 2. Total apoE
levels were positively associated with total plasma chol-
esterol levels (Spearman’s ρ = 0.6552, p = 0.0005) and this
association was driven by the apoE3 isoform levels
(Spearman’s ρ = 0.6744, p = 0.0003). Total plasma apoE
levels were also positively related to plasma LDL
cholesterol levels (Spearman’s ρ = 0.4319, p = 0.0351),
which is similar to the link between apoE and total
cholesterol driven by apoE3 levels (Spearman’s ρ =
0.4806, p = 0.0174). We found no statistically
Table 1 Study subject characteristics
N Age at investigation
(years)
Race (% White) Body mass index Diabetes (% yes) Dementia family
history (% yes)
Education (years)
Total 128 63.1 ± 10.6 89.8 26.1 ± 4.4 3.1 81.3 15.9 ± 2.3
Females 91 61.8 ± 10.4 87.9 25.8 ± 4.8 2.2 81.3 15.9 ± 2.3
Males 37 66.3 ± 10.5 94.6 27.0 ± 3.3 5.4 81.1 16.0 ± 2.3
Imaged subjects 25 65.7 ± 5.0 88.0 26.7 ± 3.8 8 100 16 ± 2.6
Females 17 65.2 ± 5.3 82.4 25.7 ± 4 0 100 15.8 ± 2.8
Males 8 64.4 ± 5.6 100 28.7 ± 2.5 25 100 16.6 ± 2.3
Data presented as mean ± standard deviation or percentage
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significant associations between apoE4 isoform levels
and any of the plasma lipids.
Plasma apoE levels differ between males and females
Both total plasma apoE (35.67 (16.84–137.52) μg/ml ver-
sus 32.58 (15.49–54.85) μg/ml, p = 0.0193) and apoE4
(5.03 (0.01–18.61) μg/ml versus 3.67 (0.15–11.37) μg/ml,
p = 0.0267) levels were significantly higher in females (n =
91) versus males (n = 37), whereas plasma apoE3 levels
did not significantly differ between the sexes. The overall
apoE isoform distribution in total apoE did not differ
between sexes with similar ratios of apoE3 and apoE4 to
total apoE.
Plasma apoE levels increase with age in females
The identified gender differences prompted us to examine
potential apoE–age associations in females (n = 91) and
males (n = 37) separately. Total apoE and apoE3 levels
were weakly but significantly associated with age in fe-
males only (Spearman’s ρ = 0.2214, p = 0.0349 and Spear-
man’s ρ = 0.2264, p = 0.0309). Using an arbitrary cutoff
point to divide older versus younger individuals into two
groups (≤60 or ≥60 years of age), the older females dis-
played 11.5% higher total plasma apoE levels (p = 0.048)
driven by an 11.7% increase in apoE3 levels (p = 0.045).
Females aged 60 years or older exhibited 33% higher total
apoE levels driven by an increase in apoE3 levels only,
compared with their male counterparts (p = 0.001).
Fig. 1 Plasma apoE levels. Plasma levels of total apoE, apoE3 and apoE4 isoforms in the total APOE ε3/ε4 cohort studied (n = 128) and in the
imaged cohort (n = 25) (a). Correlation between plasma total apoE levels and the individual apoE3 (b) and apoE4 (c) isoform levels, and between
plasma apoE3 and apoE4 isoform levels (d). apoE apolipoprotein E
Table 2 Plasma lipid profiles in individuals that had undergone
brain imaging (n = 24)
Plasma lipid
Total cholesterol (mg/dl) 187.4 ± 27.9
Triglycerides (mg/dl) 116.0 ± 58.5
HDL cholesterol (mg/dl) 62 ± 30.4
LDL cholesterol (ng/dl) 107.7 ± 19.4
Data presented as mean ± standard deviation
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Associations between plasma apoE levels, regional CMRgl
and GMV
To assess whether peripheral apoE levels are associated
with GMV and CMRgl, we consulted imaging data from
25 individuals who had undergone FDG-PET to deter-
mine CMRgl and MRI to determine regional GMV dur-
ing the same visits as when blood samples were drawn.
The characteristics of the individuals who underwent
imaging are summarized in Table 1. Given our limited
sample size and the potential number of comparisons
we could make, we focused our examination on the as-
sociation of the apoE4/apoE3 ratio with CMRgl and with
GMV while also exploring such correlation with each
apoE isoform. We first investigated whether the relative
ratios between the apoE4 and apoE3 isoforms were
negatively associated with regional CMRgl and GMV
because numerous studies have attributed a gain of toxic
function to the APOE ε4 gene product [22], and hence
lower levels of this isoform may be beneficial. We found
that higher apoE4/apoE3 ratios were indeed mainly asso-
ciated negatively with measures on both the FDG-PET
and MRI scans. Specifically, higher apoE4/apoE3 ratios
were associated with glucose hypometabolism in the
right hippocampus (Fig. 2 and Table 3). This p value sur-
vived multiple comparisons at the 0.05 level using SVC.
A negative correlation was further observed between
CMRgl and levels of the apoE4 isoform in the left infer-
ior frontal orbital region (p = 0.000432), and a negative
correlation with CMRgl and apoE3 isoform in the right
frontal medial orbital (p = 0.00126) (Table 3). Similarly,
higher apoE4/apoE3 ratios were negatively associated
with GMV in the following common regions of GMV
decline with AD: posterior cingulum, left hippocampus,
left and right lateral temporal, left medial temporal and
right precuneus (Fig. 2 and Table 3). Only the negative
association of GMV and E4/E3 ratio in the posterior
cingulum survived corrections at a 0.05 level with SVC.
Neuropsychological test results and correlations with
apoE levels
We next assessed whether the identified associations
could be reflected in scores on neuropsychological
tests assessing verbal comprehension, working mem-
ory, word retrieval, attention and arithmetic capabil-
ities mainly connected to the frontal and temporal
lobes. Neuropsychological test battery results from the
entire Arizona APOE Cohort (in total n = 71 APOE ε4
homozygotes and n = 194 heterozygotes as well as n =
356 non-APOE ε4 carriers used as controls) were
published previously [37].
Fig. 2 Negative associations between plasma apoE4/apoE3 ratio, CMRgl and GMV. Statistical brain maps depicting negative correlations (specific
details in Table 3) between the plasma relative apoE4/apoE3 ratio and regional CMRgl (top row) and GMV (bottom row) in brain areas overlapping
with (blue) or outside (light blue) areas commonly affected in AD (purple) [53] (Color figure online). AD Alzheimer’s disease
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We used multivariable regression analysis to assess po-
tential associations between plasma total apoE, apoE iso-
form levels, apoE4/apoE3 ratios and test scores for
global cognition as well as scores from neuropsycho-
logical tests assessing performance in four cognitive do-
mains: memory, language, executive and spatial
functions. We found no correlation between global cog-
nition scores and apoE levels in the two cohorts (data
not shown) and our assessment of associations between
scores from individual cognitive domain testing and
apoE isoforms all turned out essentially negative when
correcting for multiple testing (Bonferroni, four cogni-
tive domains) (data not shown).
With significant differences in apoE levels between
males and females, we explored sex-dependent associa-
tions between apoE levels and cognitive test scores.
Splitting the large group into females (n = 91) versus
males (n = 37) we found two associations between
plasma apoE levels and cognition scores that remained
significant after corrections, in females only. Total
plasma apoE levels were positively associated with scores
on the revised Wechsler Adult Intelligence Scale similar-
ities subtest (WAIS-R similar) (Spearman’s ρ = 0.3691, p
= 0.0003, corrected p = 0.0012). This correlation was
driven by plasma apoE3 levels which were positively as-
sociated with scores on the WAIS-R similar test (Spear-
man’s ρ = 0.3081, p = 0.003, corrected p = 0.0012). Hence,
higher apoE (apoE3) levels were linked to better per-
formance on the verbal reasoning (similarities) subtest
of the WAIS-R test in females only.
Discussion
Identification of APOE ε4 phenotypical characteristics in
humans should promote experimental hypothesis-driven
research linking pathological cell and molecular pro-
cesses to APOE ε4. We recently reported that APOE ε4
carriers have decreased levels of plasma apoE driven by
a specific decrease in the apoE4 isoform levels [33]. We
speculated that peripheral alterations in apoE concentra-
tions predispose APOE ε4 carriers to processes leading
to AD rather than cause the disease because in our pre-
vious study we found no difference in apoE levels be-
tween patients and controls. Interestingly, one study
found that total plasma apoE levels were negatively
linked to memory and verbal memory in older individ-
uals when correcting for APOE ε4 carrier status [44],
and results from the ADNI [45] proposed that lower
total apoE levels were associated with smaller hippocam-
pal size and that the association was driven by APOE ε4
status. Whether these associations can be traced to indi-
vidual apoE isoform concentrations rather than total
apoE levels remains to be investigated. We here quanti-
fied total plasma apoE and individual apoE isoform
levels in nondemented individuals with an APOE ε4/ε3
genotype. We were interested to see whether the protein
levels of the apoE4 risk isoform versus apoE3 in plasma
could be associated with phenotypical characteristics re-
ported in APOE ε4 carriers [11]. Our results indicated
that the relative distribution between the risk-isoform
apoE4 and the apoE3 isoform is of importance because a
higher relative ratio of apoE4/apoE3 was linked to glu-
cose hypometabolism and reduced GMV, for instance in
the posterior and anterior cingulate areas. Hypometabo-
lism in the medial temporal and parietal areas was pro-
posed previously to predict cognitive decline in
cognitively normal individuals [46], and in a large study
including 600 cognitively normal individuals hypometa-
bolism was associated with amyloid pathology as
assessed using Pittsburgh compound B (PiB)-PET [47].
It was further found that APOE ε4 carriers exhibited
marginally lower metabolism specifically in the posterior
cingulate compared with noncarriers and the authors
proposed that the APOE-associated observations were
mediated through Aβ plaque load (PiB retention). Previ-
ous studies have shown that APOE ε4 carriers of similar
age to those investigated here exhibit significant amyloid
pathology even in the absence of cognitive symptoms
[5]. A major weakness of the current study is that the
studied individuals did not undergo CSF sampling and
hence CSF AD biomarkers levels as surrogate markers of
amyloid and tau pathology were not available.
Exactly how the relative ratio of apoE4 over apoE3 iso-
form levels in plasma can be related to the described
structural and metabolic differences in the brain is not
clear and linking peripheral apoE levels to processes in
the brain is controversial because peripheral apoE does
not cross the blood–brain barrier (BBB) [48]. Of note,
we found that females exhibited higher apoE4 isoform
levels than males and that the apoE3 levels were posi-
tively associated with age in females only. Results re-
ported previously from the prospective study of the
Danish general population also demonstrated an age-
Table 3 Correlations between regional glucose metabolism,
gray matter volume and plasma apoE concentrations
apoE4/E3 ratio
negative
association
Brain region Coordinates
(X, Y, Z)
p value
CMRgl Hippocampus_R 26, –12, –12 2.49 × 10–4 a
GMV Cingulate_Post 4, –40, 21 5.60 × 10–4 b
Hippocampus_L –16, –34, 9 4.91 × 10–3
Lateral Temporal_L –48, –64, –3 2.81 × 10–3
Lateral Temporal_R 60, –31, 13 1.83 × 10–4
Medial Temporal_L –16, –34, 9 4.91 × 10–3
Precuneus_R 8, –43, 18 1.87 × 10–3
a Survived correction at a 0.05 level
b Survived correction at a 0.059 level
CMRgl cerebral metabolic rate of glucose, GMV gray matter volume
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associated increase in levels of apoE (total levels) in both
females and males; however, the increase in males
appeared to plateau earlier than the increased levels
found in females [34]. There could be several causes of
the age-associated increase of apoE3 but not apoE4 that
we observed in females, including altered levels of vari-
ous sex hormones due to menopause; however, the lack
of effect on the levels of apoE4 proposes differential ef-
fects of sex on different apoE isoforms. We speculate
that an increased relative ratio of apoE4 over apoE3 may
be ‘risky’ and that the levels of apoE3 are age-
dependently upregulated as a protective feature in
females who generally are at higher risk of AD [49].
Intriguingly, the specific role of apoE3 in APOE ε3/ε4 car-
riers is not well understood. The risk of developing AD is
known to be higher in APOE ε3/ε4 carriers than in APOE
ε2/ε4 carriers [3] and also the lipid and receptor binding
capacities differ between the apoE isoforms [50]. If assum-
ing a loss of function of the apoE4 isoform, a compensa-
tory upregulation of the non-apoE4 isoform—apoE3 in
the case of the herein studied individuals—may be benefi-
cial. A full compensatory mechanism appears not to be
present, however, as indicated by our previous findings
showing lower plasma total apoE levels in APOE ε3/ε4
carriers versus APOE ε3/ε3 carriers [33]. Overall low total
apoE levels were shown to increase the risk of AD and of
other types of dementia in the Danish general population
[34], but the question remains whether increased levels of
all isoforms including apoE4 may be beneficial or not.
Future studies further need to address whether the
described age-associated and sex-associated effects also
apply to apoE levels in CSF, in which we have previously
shown that the ratio between the different apoE isoforms
in total apoE differ from those in plasma [33].
In relation to the effect of sex, when exploring whether
the variation in plasma apoE could be linked to cognitive
performance in four major domains (memory, language,
executive and spatial functions) we found only two weak
correlations which were observed in females only. Hence
as expected when studying a cohort that is cognitively
intact (with little variation in cognitive performance), we
did not find any strong correlations between plasma
apoE levels and neuropsychological test results; however,
our data do suggest the presence of a gender-specific
effect on these correlations. Because of our limited sam-
ple size, future studies of larger cohorts are necessary to
assess the specificity and significance of our observations
linking plasma apoE levels to imaging findings and
neuropsychological test outcomes.
The observed low levels of the apoE4 isoform with
regard to total apoE levels are in line with our results
reported previously [33]. However, the differences in
apoE isoform levels between the sexes as well as an age-
related increase in apoE3 in females only were not
observed in our previous study [33]. Differences in cohort
size and age of the included individuals may be factors
that have influenced the outcome of the two studies. The
lack of correlation between the apoE3 and apoE4 isoforms
in plasma was surprising and needs further attention. It
has been shown that the turnover rate differs between dif-
ferent apoE isoforms in plasma, with the apoE4 turnover
rate almost 4-fold faster than that for apoE2 in APOE ε2/
ε4 individuals [31]. As discussed before [33], it is not clear
whether the apoE4 isoform levels result from fast degrad-
ation paralleled by a lack of compensatory upregulation of
apoE4 synthesis or whether the synthesis of apoE4 per se
is lower than that of other apoE isoforms due to differ-
ences at the expression and/or translation level in the per-
iphery. Given our current results and previous results of a
specific reduction in the apoE4 isoform in APOE hetero-
zygous individuals [33], further studies are necessary to
confirm that the reported differences are not due to alter-
ations in the allele-specific expression of apoE.
Conclusions
The current study provides the first evidence linking
plasma levels of the individual apoE3 and apoE4 iso-
forms to structural and metabolic changes in the brains
of cognitively intact APOE ε3/ε4 carriers. Specifically,
the relative ratio between plasma levels of apoE4 and
apoE3 appears to be of importance. Our study further
provides new insights into sex-dependent differences in
plasma apoE levels, with females exhibiting higher levels
of the apoE4 isoform than males and increasing plasma
apoE3 concentrations as a function of age. The exact
relevance of these findings needs to be determined be-
cause female APOE ε4 carriers are at higher risk of AD
than males [51, 52]. We conclude that peripheral levels
of apoE and the isoform composition of total apoE levels
are important features to consider with regard to risk
and etiology of AD in carriers of the APOE ε4 risk allele.
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